Compare Expensify Inc (EXFY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Tango Therapeutics Inc. — how do they compare? Expensify Inc trades at $2.44 (market cap $223.41M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 16.7× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Tango Therapeutics Inc. for 0 Days on average.
| EXFY | TNGX | |
|---|---|---|
Market Cap | $223.41M | $3.74B |
Volume | 450,483 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $2.72 | $32.90 |
52-Week Low | $0.75 | $7.50 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $163.03M | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.44, showing stability with no recent price movement. The stock exhibits a bullish technical signal with strong moving average support, though oscillators remain neutral. Fundamentally, the company maintains a 48.7% gross margin but reports negative net income margins and ROE. Recent quarterly earnings show mixed results with two beats and one miss. Analyst sentiment is positive with a 50% buy rating and $13.75 consensus price target, representing significant upside potential from current levels.
The outlook remains cautiously optimistic as Expensify expands its AI-native integrations and European card offerings, though profitability challenges and competitive pressures persist. Key opportunities include the company's strategic shift toward AI solutions and international expansion, while risks center on achieving sustainable profitability and managing the transition from legacy products.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
